A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Numakura, Tadahisa, Murakami, Koji, Tamada, Tsutomu, Yamaguchi, Chiaki, Inoue, Chihiro, Ohkouchi, Shinya, Tode, Naoki, Sano, Hirohito, Aizawa, Hiroyuki, Sato, Kei, Mitsune, Ayumi, Kurosawa, Hajime, Nakazawa, Toru, Sugiura, Hisatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646347/
https://www.ncbi.nlm.nih.gov/pubmed/35945009
http://dx.doi.org/10.2169/internalmedicine.0104-22
_version_ 1784827145136111616
author Numakura, Tadahisa
Murakami, Koji
Tamada, Tsutomu
Yamaguchi, Chiaki
Inoue, Chihiro
Ohkouchi, Shinya
Tode, Naoki
Sano, Hirohito
Aizawa, Hiroyuki
Sato, Kei
Mitsune, Ayumi
Kurosawa, Hajime
Nakazawa, Toru
Sugiura, Hisatoshi
author_facet Numakura, Tadahisa
Murakami, Koji
Tamada, Tsutomu
Yamaguchi, Chiaki
Inoue, Chihiro
Ohkouchi, Shinya
Tode, Naoki
Sano, Hirohito
Aizawa, Hiroyuki
Sato, Kei
Mitsune, Ayumi
Kurosawa, Hajime
Nakazawa, Toru
Sugiura, Hisatoshi
author_sort Numakura, Tadahisa
collection PubMed
description BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
format Online
Article
Text
id pubmed-9646347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-96463472022-11-18 A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review Numakura, Tadahisa Murakami, Koji Tamada, Tsutomu Yamaguchi, Chiaki Inoue, Chihiro Ohkouchi, Shinya Tode, Naoki Sano, Hirohito Aizawa, Hiroyuki Sato, Kei Mitsune, Ayumi Kurosawa, Hajime Nakazawa, Toru Sugiura, Hisatoshi Intern Med Case Report BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination. The Japanese Society of Internal Medicine 2022-08-10 2022-10-15 /pmc/articles/PMC9646347/ /pubmed/35945009 http://dx.doi.org/10.2169/internalmedicine.0104-22 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Numakura, Tadahisa
Murakami, Koji
Tamada, Tsutomu
Yamaguchi, Chiaki
Inoue, Chihiro
Ohkouchi, Shinya
Tode, Naoki
Sano, Hirohito
Aizawa, Hiroyuki
Sato, Kei
Mitsune, Ayumi
Kurosawa, Hajime
Nakazawa, Toru
Sugiura, Hisatoshi
A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
title A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
title_full A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
title_fullStr A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
title_full_unstemmed A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
title_short A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
title_sort novel development of sarcoidosis following covid-19 vaccination and a literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646347/
https://www.ncbi.nlm.nih.gov/pubmed/35945009
http://dx.doi.org/10.2169/internalmedicine.0104-22
work_keys_str_mv AT numakuratadahisa anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT murakamikoji anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT tamadatsutomu anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT yamaguchichiaki anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT inouechihiro anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT ohkouchishinya anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT todenaoki anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT sanohirohito anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT aizawahiroyuki anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT satokei anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT mitsuneayumi anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT kurosawahajime anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT nakazawatoru anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT sugiurahisatoshi anoveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT numakuratadahisa noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT murakamikoji noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT tamadatsutomu noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT yamaguchichiaki noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT inouechihiro noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT ohkouchishinya noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT todenaoki noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT sanohirohito noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT aizawahiroyuki noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT satokei noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT mitsuneayumi noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT kurosawahajime noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT nakazawatoru noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview
AT sugiurahisatoshi noveldevelopmentofsarcoidosisfollowingcovid19vaccinationandaliteraturereview

Ejemplares similares